

**Patient Information:**

- **Name:** Harold Joseph Densmore
- **Patient ID:** SYN142
- **DOB:** 16/02/1954

**Primary Diagnosis:** BRAF V600E mutant NSCLC with liver metastases (27/05/2021)

- **Driver Mutation:** BRAF V600E (IHC confirmed, verified on MSK-IMPACT panel)
- **PD-L1 Status:** TPS 65%, CPS 72, IC 3+ (SP263)

**Treatment History:** Dabrafenib (150 mg BID) + Trametinib (2 mg QD)

**Clinical Course:** Mr. Densmore began on BRAF-MEK inhibition on 18/06/2021 with excellent initial response (primary lesion shrank from 5.2 to 2.1 cm). Side effects included intermittent Grade 2 pyrexia, managed with treatment pauses. By mid August 2022, new hepatic lesions developed, and therapy was changed to nivolumab + ipilimumab. Severe immune-related colitis (Grade 3) prompted discontinuation after 2 cycles.

A 3L regimen of docetaxel was initiated with neutropenic fever after cycle 2. ECOG deteriorated to 3. Disease progression in the liver led to refractory hepatic dysfunction.

**Comorbidities:**

- T2DM (HbA1c 8.1%)
- Cirrhosis secondary to alcohol (Child-Pugh B)
- Macrocytic anemia (Hb 9.8 g/dL, MCV 102 fL)

**Laboratory (Final Admission):**

- Bilirubin: 3.2 mg/dL
- ALT/AST: 180/202 U/L
- INR: 1.8
- Albumin: 2.6 g/dL

**Date of Death:** 13/03/2023 **Cause of Death:** Hepatic failure with multiorgan dysfunction